Adding adavosertib to chemotherapy improved PFS [median, 7.9 vs. 7.3 months] in patients with TP53-mutated, platinum- sensitive ovarian cancer treated with adavosertib (A + C) plus carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel group (P + C) in the phase II clinical trial NCT01357161. This evidence concerns the gene TP53 and ovarian cancer.